Home · Stock · BSX

BSX Boston Scientific Corp

Which ETFs hold BSX? Boston Scientific Corp is held by 4 funds tracked by ETFpeek.

Held by 4 funds todayData as of 31 Aug 2026
HealthcareMedical Devices
$42.04
-55.9% 1y
$41.3852-week range$105.65
Market cap
$61.7B
P/E
17.0
3-month
-6.1%
CEO
Mr. Michael F. Mahoney
Revenue · last 4 qtrs (+7.5% YoY)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Provider

Currently Held By

VANGUARD
VUG
Weight in fund0.11%
Shares held9,129,012
Market value$440.9M
View fund →
SMARTSHARES
USG
Smart US Large Growth ETF
via VUG
Weight in fund0.11%
Shares held—
Market value$730K NZD
View fund →
VANGUARD
VOO
Weight in fund0.11%
Shares held39,489,384
Market value$1.91B
View fund →
SMARTSHARES
USF
Smart US 500 ETF
via VOO
Weight in fund0.11%
Shares held—
Market value$1.4M NZD
View fund →
Not held by the selected provider.
last 90 days
Net flow (90d):+$14.2M·10 BUY / 0 SELL·score ≥ 40
DatePersonActionPlanSharesValueScore i
25 Aug 2026
Susan E Morano
Director / Other
BUYDiscretionary2,040$100K80
11 Aug 2026
Emily Woodworth
Senior VP, Global Controller & Chief Accounting Officer
BUYDiscretionary2,930$150K80
10 Aug 2026
Jonathan Monson
Executive VP & CFO
BUYDiscretionary9,908$500K80
5 Aug 2026
David C Habiger
Director / Other
BUYDiscretionary2,100$100K80
4 Aug 2026
David C Habiger
Director / Other
BUYDiscretionary140$7K60
3 Aug 2026
Michael F Mahoney
Chairman, President & CEO
BUYDiscretionary208,359
2 tranches
$10.1M100
3 Aug 2026
David C Habiger
Director / Other
BUYDiscretionary1,042$50K80
31 Jul 2026
Joseph Michael Fitzgerald
Executive VP & Group President of Cardiovascular
BUYDiscretionary64,198$3.0M100
31 Jul 2026
Edward J Ludwig
Director / Other
BUYDiscretionary5,000$227K80
Net flow (90d):+$14.2M·10 BUY / 0 SELL·showing all trades
DatePersonActionPlanSharesValueScore i
25 Aug 2026
Susan E Morano
Director / Other
BUYDiscretionary2,040$100K80
11 Aug 2026
Emily Woodworth
Senior VP, Global Controller & Chief Accounting Officer
BUYDiscretionary2,930$150K80
10 Aug 2026
Jonathan Monson
Executive VP & CFO
BUYDiscretionary9,908$500K80
5 Aug 2026
David C Habiger
Director / Other
BUYDiscretionary2,100$100K80
4 Aug 2026
David C Habiger
Director / Other
BUYDiscretionary140$7K60
3 Aug 2026
Michael F Mahoney
Chairman, President & CEO
BUYDiscretionary208,359
2 tranches
$10.1M100
3 Aug 2026
David C Habiger
Director / Other
BUYDiscretionary1,042$50K80
31 Jul 2026
Joseph Michael Fitzgerald
Executive VP & Group President of Cardiovascular
BUYDiscretionary64,198$3.0M100
31 Jul 2026
Edward J Ludwig
Director / Other
BUYDiscretionary5,000$227K80
Data: Finnhub (SEC Form 4 filings) · Score: ETFpeek heuristic
0 trades
DateFundDirectionShares Changed% Δ ETF i% Δ Position i
No trades recorded yet.
No trade history for SmartShares funds — their underlying ETFs are passive index trackers, so day-to-day rebalancing is minimal.

More stocks in these funds